Patients The need for a science-first mindset: The vaccine landscape ... In a new pharmaphorum podcast, Rebecca Catterick, previously at Sanofi, discusses the decline in vaccination rates.
News FDA clears new, safer regimen for Lilly's Alzheimer's drug Eli Lilly has won FDA approval for a new regimen for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of side effects.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
